This update was written automatically with AI from market data and news wire reports, and published without review by a person.
Key Takeaways
- The Bank of Japan (BoJ) maintained its short-term policy rate at 1.25% but declared that underlying inflation has reached levels consistent with its 2% price stability target, signaling a definitive shift toward further rate hikes.
- Sanofi (SASY) reported a 22% surge in Q3 business EPS to €3.55, significantly beating analyst estimates of €2.80, driven by a 35% jump in sales of its blockbuster drug Dupixent.
- The French economy unexpectedly contracted by 0.1% in Q3 2026, defying forecasts for growth as consumer spending fell 0.5% in September, highlighting deepening fragility in the Eurozone’s second-largest economy.
- Precious metals faced sharp selling pressure, with Spot Gold retreating nearly 1% to $3,983.79/oz and Silver sliding 3% to $50.82/oz as markets adjusted to shifting central bank expectations.
- Geopolitical tensions escalated as Russia claimed to have intercepted over 1,000 Ukrainian drones overnight, an unprecedented wave that forced the closure of multiple Moscow airports and disrupted regional infrastructure.
BoJ Enters New Phase of Monetary Policy
Bank of Japan Governor Kazuo Ueda confirmed on Friday that the central bank has effectively reached its long-sought 2% inflation goal. While the BoJ kept interest rates steady at 1.25% in an 8-1 vote, Ueda emphasized that policymakers will no longer issue formal announcements on achieving the target, instead focusing on keeping inflation from overshooting.
Ueda noted that while financial conditions in Japan remain supportive, the bank will closely monitor wage growth sustainability and economic risks at each meeting. Analysts suggest the BoJ’s hawkish tone, despite the hold, keeps a December rate hike firmly on the table as core inflation remains stable near the target.
Sanofi Outperforms on Dupixent Strength
French pharmaceutical giant Sanofi (SASY) delivered a robust third-quarter performance, prompting management to upgrade its full-year 2026 guidance. The company now expects low-teens sales growth and mid-teens business EPS growth at constant exchange rates.
The results were anchored by Dupixent net product sales of €5.69B, which surpassed the €5.2B consensus. Despite a 6.6% decline in vaccine sales, the company's business operating income reached €5.43B, well above the anticipated €4.33B, reflecting strong cost discipline and the successful launch of new pharmaceutical products.
European Economic Data and Market Volatility
In contrast to the corporate strength at Sanofi, broader French economic indicators painted a grim picture. France’s Q3 GDP fell 0.1%, missing the 0.1% growth estimate, while September consumer spending dropped 0.5% month-on-month. This data suggests that high energy costs and political uncertainty are weighing heavily on domestic demand.
Commodity markets reacted to the shifting global landscape with significant retreats. Spot Gold fell below the $4,000 mark to trade at $3,983.79/oz, while Silver prices plummeted 3%, reaching $50.82/oz. The sell-off in precious metals appears driven by a combination of a stronger dollar and investor repositioning ahead of upcoming major central bank decisions.
Unprecedented Drone Activity in Russia
On the geopolitical front, the conflict in Eastern Europe reached a new peak of intensity. Russian authorities reported the downing of 1,043 Ukrainian drones across several regions overnight. The massive scale of the attack triggered the closure of all four major Moscow airports—Domodedovo, Vnukovo, Sheremetyevo, and Zhukovsky—leading to hundreds of flight cancellations and delays.
The strikes reportedly targeted energy and logistics infrastructure, including an oil refinery in the Samara region. This escalation continues to inject significant volatility into global energy markets and heightens the risk premium associated with regional stability.
Automated market updates written with AI from market data and news wire reports, published without human review.